Mortality As a Measure of Treatment Effect in Clinical Trials Recruiting Critically Ill Patients*

被引:7
|
作者
Friedrich, Jan O. [1 ,2 ]
Harhay, Michael O. [3 ]
Angus, Derek C. [4 ]
Burns, Karen E. A. [1 ,2 ]
Cook, Deborah J. [5 ]
Fergusson, Dean A. [6 ]
Finfer, Simon [7 ]
Hebert, Paul [8 ]
Rowan, Kathy [9 ]
Rubenfeld, Gordon [1 ,2 ,10 ]
Marshall, John C. [1 ,11 ]
机构
[1] Univ Toronto, St Michaels Hosp, Dept Crit Care Med, Toronto, ON, Canada
[2] Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON, Canada
[3] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA USA
[4] Univ Pittsburgh, CRISMA Ctr, Med Ctr, Pittsburgh, PA USA
[5] McMaster Univ, Hamilton, ON, Canada
[6] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[7] George Inst, Sydney, NSW, Australia
[8] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ, Canada
[9] Intens Care Natl Audit & Resource Ctr ICNARC, London, England
[10] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[11] Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON, Canada
基金
美国国家卫生研究院;
关键词
ARDS; critical care; mortality; sepsis; trials; RESPIRATORY-DISTRESS-SYNDROME; INTENSIVE-CARE; SEVERE SEPSIS; SEPTIC SHOCK; EFFICACY; SAFETY; MULTICENTER; OUTCOMES; HYDROCORTISONE; VENTILATION;
D O I
10.1097/CCM.0000000000005721
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
OBJECTIVES:All-cause mortality is a common measure of treatment effect in ICU-based randomized clinical trials (RCTs). We sought to understand the performance characteristics of a mortality endpoint by evaluating its temporal course, responsiveness to differential treatment effects, and impact when used as an outcome measure in trials of acute illness. DATA SOURCES:We searched OVID Medline for RCTs published from 1990 to 2018. STUDY SELECTION:We reviewed RCTs that had randomized greater than or equal to 100 patients, were published in one of five high-impact general medical or eight critical care journals, and reported mortality at two or more distinct time points. We excluded trials recruiting pediatric or neonatal patients and cluster RCTs. DATA EXTRACTION:Mortality by randomization group was recorded from the article or estimated from survival curves. Trial impact was assessed by inclusion of results in clinical practice guidelines. DATA SYNTHESIS:From 2,592 potentially eligible trials, we included 343 RCTs (228,784 adult patients). While one third of all deaths by 180 days had occurred by day 7, the risk difference between study arms continued to increase until day 60 (p = 0.01) and possibly day 90 (p = 0.07) and remained stable thereafter. The number of deaths at ICU discharge approximated those at 28-30 days (95% [interquartile range [IQR], 86-106%]), and deaths at hospital discharge approximated those at 60 days (99% [IQR, 94-104%]). Only 13 of 43 interventions (30.2%) showing a mortality benefit have been adopted into widespread clinical practice. CONCLUSIONS:Our findings provide a conceptual framework for choosing a time horizon and interpreting mortality outcome in trials of acute illness. Differential mortality effects persist for 60 to 90 days following recruitment. Location-based measures approximate time-based measures for trials conducted outside the United States. The documentation of a mortality reduction has had a modest impact on practice.
引用
收藏
页码:222 / 230
页数:9
相关论文
共 50 条
  • [1] Four Decades of Randomized Clinical Trials Influencing Mortality in Critically Ill and Perioperative Patients
    Romero, Carolina S.
    Romero, Esther
    Maimieri, Nicolo
    Popp, Maria
    Marchetti, Cristiano
    Lombardi, Gaetano
    Ortalda, Alessandro
    Zangrillo, Alberto
    Landoni, Giovanni
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2022, 36 (08) : 3327 - 3333
  • [2] Clinical Trials in the Critically Ill
    Guerin, Claude
    Argaud, Laurent
    CRITICAL CARE MEDICINE, 2020, 48 (05) : E435 - E435
  • [3] The design of randomized clinical trials in critically ill patients
    Hébert, PC
    Cook, DJ
    Wells, G
    Marshall, J
    CHEST, 2002, 121 (04) : 1290 - 1300
  • [4] Quantifying Threats to the Feasibility of Clinical Trials in Critically Ill Patients
    Rose, L.
    Burns, K. E.
    Smith, O. M.
    Marshall, J. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [5] Improving clinical trials in the critically ill
    Angus, Derek C.
    Mira, Jean-Paul
    Vincent, Jean-Louis
    CRITICAL CARE MEDICINE, 2010, 38 (02) : 527 - 532
  • [6] Do trials that report a neutral or negative treatment effect improve the care of critically ill patients? No
    Vincent, Jean-Louis
    Marini, John J.
    Pesenti, Antonio
    INTENSIVE CARE MEDICINE, 2018, 44 (11) : 1989 - 1991
  • [7] Do trials that report a neutral or negative treatment effect improve the care of critically ill patients? No
    Jean-Louis Vincent
    John J. Marini
    Antonio Pesenti
    Intensive Care Medicine, 2018, 44 : 1989 - 1991
  • [8] HYPOTHYROXINEMIA AND MORTALITY IN CRITICALLY ILL PATIENTS
    SLAG, MF
    MORLEY, JE
    ELSON, MK
    LABROSSE, K
    CROWSON, TW
    NUTTALL, FQ
    SHAFER, RB
    CLINICAL RESEARCH, 1980, 28 (04): : A762 - A762
  • [9] Predicting Mortality in Critically Ill Patients
    Teasdale, Graham M.
    Stocchetti, Nino
    Maas, Andrew I.
    Murray, Gordon D.
    CRITICAL CARE MEDICINE, 2015, 43 (10) : E471 - E472
  • [10] THROMBOPROPHYLAXIS AND MORTALITY CRITICALLY ILL PATIENTS
    Stanescu, D. O.
    Garcia Olivares, P.
    Hernangomez, A. M.
    Del Valle, M.
    Buitrago, G.
    Estevez, M. A.
    Sagra, F. J.
    Ramirez, C.
    Caciano, C.
    INTENSIVE CARE MEDICINE, 2013, 39 : S283 - S283